Yale School of Medicine: For Type 1 Diabetes, Teplizumab Preserves Beta Cell Function and Shows Significant Other Benefits
October 19, 2023
October 19, 2023
NEW HAVEN, Connecticut, Oct. 19 (TNSres) -- The Yale University School of Medicine issued the following news:
Teplizumab (Tzield(R)) helps preserve the ability of children and adolescents with new-onset type 1 diabetes to make their own insulin, a phase 3 trial finds. The drug was approved by the U.S. Food and Drug Administration (FDA) in November 2022 after it was shown to delay the onset of stage 3 type 1 diabetes.
Now, the PROTECT study has evaluated whether it could . . .
Teplizumab (Tzield(R)) helps preserve the ability of children and adolescents with new-onset type 1 diabetes to make their own insulin, a phase 3 trial finds. The drug was approved by the U.S. Food and Drug Administration (FDA) in November 2022 after it was shown to delay the onset of stage 3 type 1 diabetes.
Now, the PROTECT study has evaluated whether it could . . .